Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer
ChiCTR2400081341Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Union Hospital. Primary endpoint: Surgical conversion rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
surufatinibgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400081341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081341.